Inhibition of CYP2B6 by medicinal plant extracts: Implication for use of efavirenz and nevirapine based highly active anti-retroviral therapy (HAART) in resource-limited settings

Molecules

Volumn 21, Issue 2, 2016, Pages

  Thomford, Nicholas E ^a,b   Awortwe, Charles ^c   Dzobo, Kevin ^a   Adu, Faustina ^b   Chopera, Denis ^a   Wonkam, Ambroise ^a   Skelton, Michelle ^a   Blackhurst, Dee ^a   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE COAST   (Ghana)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

CYP450; Herb drug interactions; Recombinant human CYPs; Reversible inhibition; Time dependent inhibition

Indexed keywords

BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN; CYTOCHROME P450 2B6; CYTOCHROME P450 2B6 INHIBITOR; EFAVIRENZ; NEVIRAPINE; PLANT EXTRACT;

ANGIOSPERM; CHEMISTRY; GENETICS; HERB DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MEDICINAL PLANT; METABOLISM;

ANGIOSPERMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2B6 INHIBITORS; HERB-DRUG INTERACTIONS; HUMANS; NEVIRAPINE; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84964678029     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21020211     Document Type: Article

References (57)

1. Basavaraj, K.H.; Navya, M.A.; Rashmi, R. Quality of life in HIV/AIDS. Indian J. Sex. Transm. Dis. 2010, 31, 75-80. [CrossRef] [PubMed]
2. Oguntibeju, O.O. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS 2012, 4, 117-124. [CrossRef] [PubMed]
3. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents;World Health Organization: Geneva, Switzerland, 2010.
4. Bhatt, N.B.; Baudin, E.; Meggi, B.; da Silva, C.; Barrail-Tran, A.; Furlan, V.; Grinsztejn, B.; Bonnet, M.; Taburet, A.M.; Jani, I.V.; et al. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: Exposure and virological failure relationship. J. Antimicrob. Chemother. 2014, 70, 225-232. [CrossRef] [PubMed]
5. Rodney, P.; Ndjakani, Y.; Ceesay, F.K.;Wilson, N.O. Addressing the Impact of HIV/AIDS onWomen and Children in Sub-Saharan Africa: PEPFAR, the U.S. Strategy. Afr. Today 2011, 57, 64-76. [CrossRef]
6. Yimer, G.; Amogne, W.; Habtewold, A.; Makonnen, E.; Ueda, N.; Suda, A.; Worku, A.; Haefeli, W.E.; Burhenne, J.; Aderaye, G.; et al. High plasma efavirenz level and CYP2B6 ∗6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: A prospective cohort study. Pharmacogenom. J. 2012, 12, 499-506. [CrossRef] [PubMed]
7. Ward, B.A.; Gorski, J.C.; Jones, D.R.; Hall, S.D.; Flockhart, D.A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003, 306, 287-300. [CrossRef] [PubMed]
8. Haas, D.W.; Gebretsadik, T.; Mayo, G.; Menon, U.N.; Acosta, E.P.; Shintani, A.; Floyd, M.; Stein, C.M.; Wilkinson, G.R. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J. Infect. Dis. 2009, 199, 872-880. [CrossRef] [PubMed]
9. Tsuchiya, K.; Gatanaga, H.; Tachikawa, N.; Teruya, K.; Kikuchi, Y.; Yoshino, M.; Kuwahara, T.; Shirasaka, T.; Kimura, S.; Oka, S. Homozygous CYP2B6 ∗6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 2004, 319, 1322-1326. [CrossRef] [PubMed]
10. Mugusi, S.; Ngaimisi, E.; Janabi, M.; Minzi, O.; Bakari, M.; Riedel, K.D.; Burhenne, J.; Lindquist, L.; Mugusi, F.; Sandstrom, E.; et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS ONE 2012, 7. [CrossRef] [PubMed]
11. Thomford, N.E.; Dzobo, K.; Chopera, D.; Wonkam, A.; Skelton, M.; Blackhurst, D.; Chirikure, S.; Dandara, C. Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition. Pharmaceuticals 2015, 8, 637-663. [CrossRef] [PubMed]
12. Kim, H.G.; Oh, M.S. Herbal medicines for the prevention and treatment of Alzheimer's disease. Curr. Pharm. Des. 2012, 18, 57-75. [PubMed]
13. Chien, C.F.;Wu, Y.T.; Tsai, T.H. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed. Chromatogr. 2011, 25, 21-38. [CrossRef] [PubMed]
14. Dhiman, R.K.; Chawla, Y.K. Herbal medicines for liver diseases. Dig. Dis. Sci. 2005, 50, 1807-1812. [CrossRef] [PubMed]
15. Dahanukar, S.A.; Kulkarni, R.A.; Rege, N.N. Pharmacology of medicinal plants and natural products. Indian J. Pharmacol. 2000, 32, 81-118.
16. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets 2011, 12, 122-132. [CrossRef] [PubMed]
17. Kennedy, D.; Wightman, E. Herbal extracts and phytochemicals: Plant secondary metabolites and the enhancement of human brain function. Adv. Nutr. Int. Rev. J. 2011, 2, 32-50. [CrossRef] [PubMed]
18. Koffuor, G.A.; Woode, E.; Amaning-Danquah, C. Potential Drug Interactions of a Polyherbal Antihypertensive Mixture in Ghana. Pharmacol. Sin. 2011, 2, 39-45.
19. Chen, X.W.; Serag, E.S.; Sneed, K.B.; Liang, J.; Chew, H.; Pan, S.-Y.; Zhou, S.-F. Clinical herbal interactions with conventional drugs: From molecules to maladies. Curr. Med. Chem. 2011, 18, 4836-4850. [CrossRef] [PubMed]
20. He, S.M.; Chan, E.; Zhou, S.F. ADME properties of herbal medicines in humans: Evidence, challenges and strategies. Curr. Pharm. Des. 2011, 17, 357-407. [CrossRef] [PubMed]
21. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 2004, 25, 193-200. [CrossRef] [PubMed]
22. Turpeinen, M.; Zanger, U.M. Cytochrome P450 2B6: Function, genetics, and clinical relevance. Drug Metab. Drug Interact. 2012, 27, 185-197. [CrossRef] [PubMed]
23. Mo, S.L.; Liu, Y.H.; Duan, W.; Wei, M.Q.; Kanwar, J.R.; Zhou, S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 2009, 10, 730-753. [CrossRef] [PubMed]
24. Wang, H.; Tompkins, L.M. CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 2008, 9, 598-610. [CrossRef] [PubMed]
25. Turpeinen, M.; Raunio, H.; Pelkonen, O. The functional role of CYP2B6 in human drug metabolism: Substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. 2006, 7, 705-714. [CrossRef] [PubMed]
26. Zanger, U.M.; Klein, K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 2013, 4, 24. [CrossRef] [PubMed]
27. McGinnity, D.F.; Tucker, J.; Trigg, S.; Riley, R.J. Prediction of CYP2C9-mediated drug-drug interactions: A comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 2005, 33, 1700-1707. [CrossRef] [PubMed]
28. Abourashed, E. Bioavailability of Plant-Derived Antioxidants. Antioxidants 2013, 2, 309-325. [CrossRef] [PubMed]
29. Stout, C.W.; Weinstock, J.; Homoud, M.K.; Wang, P.J.N.; Estes, A.M.; Link, M.S. Herbal medicine: Beneficial effects, side effects, and promising new research in the treatment of arrhythmias. Curr. Cardiol. Rep. 2003, 5, 395-401.
30. Djuv, A.; Nilsen, O.G.; Steinsbekk, A. The co-use of conventional drugs and herbs among patients in Norwegian general practice: A cross-sectional study. BMC Complement. Altern. Med. 2013, 13. [CrossRef] [PubMed]
31. Fugh-berman, A. Herb-drug interactions. Lancet 2000, 355, 134-138. [CrossRef]
32. Chen, X.W.; Sneed, K.B.; Pan, S.Y.; Cao, C.; Kanwar, R.J.; Chew, H.; Zhou, S.F. Herb-drug interactions and mechanistic and clinical considerations. Curr. Drug Metab. 2012, 13, 640-651. [CrossRef] [PubMed]
33. Huang, S.M.; Strong, J.M.; Zhang, L.; Reynolds, K.S.; Nallani, S.; Temple, R.; Abraham, S.; Al Habet, S.; Baweja, R.K.; Burckart, G.J.; et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 2008, 48, 662-670. [CrossRef] [PubMed]
34. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S.P.; Miwa, G.; Ni, L.; et al. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J. Clin. Pharmacol. 2003, 43, 443-469.
35. Zhang, L.; Zhang, Y.D.; Zhao, P.; Huang, S.M. Predicting drug-drug interactions: An FDA perspective. AAPS J. 2009, 11, 300-306. [CrossRef] [PubMed]
36. European Medicines Agency. Guideline on the Investigation of Drug Interactions; Committee for Human Medicinal Products (CHMP): CPMP/EWP/560/560/95/Rev; London, UK, 2015; pp. 1-59.
37. Manda, V.K.; Dale, O.R.; Awortwe, C.; Ali, Z.; Khan, I.;Walker, L.; Khan, S.I. Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Front. Pharmacol. 2014, 5. [CrossRef] [PubMed]
38. Obach, R.S.;Walsky, R.L.; Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35, 246-255. [CrossRef] [PubMed]
39. Berry, L.M.; Zhao, Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab. Lett. 2008, 2, 51-59. [CrossRef] [PubMed]
40. Li, P.; Lu, C.; Balani, S.K.; Gan, L.-S. A refined cytochrome P540 IC50 shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug Metab. Dispos. 2011, 39, 1054-1057. [CrossRef] [PubMed]
41. Grimm, S.W.; Einolf, H.J.; Hall, S.D.; He, K.; Lim, H.K.; Ling, K.H.J.; Lu, C.; Nomeir, A.; Seibert, E.; Skordos, K.W.; et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: A perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab. Dispos. 2009, 37, 1355-1370. [CrossRef] [PubMed]
42. Adinortey, M.B.; Sarfo, J.K.; Quayson, E.T.;Weremfo, A.; Adinortey, C.A. Phytochemical Screening, Proximate and Mineral Composition of Launaea taraxacifolia Leaves. Res. J. Med. Plant 2012, 6, 171-179. [CrossRef]
43. Ocama, P.; Katwere, M.; Piloya, T.; Feld, J.; Opio, K.C.; Kambugu, A.; Katabira, E.; Thomas, D.; Colebunders, R.; Ronald, A. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr. Health Sci. 2008, 8, 8-12. [PubMed]
44. Price, J.C.; Thio, C.L. Liver disease in the HIV-infected individual. Clin. Gastroenterol. Hepatol. 2010, 8, 1002-1012. [CrossRef] [PubMed]
45. Husain, N.E.O.; Ahmed, M.H. Managing dyslipidemia in HIV/AIDS patients: Challenges and solutions. HIV/AIDS 2015, 7, 1-10. [PubMed]
46. Lo, J. Dyslipidemia and lipid management in HIV-infected patients. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18, 144-147. [CrossRef] [PubMed]
47. Feeney, E.R.; Mallon, P.W.G. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc. Med. J. 2011, 5, 49-63. [CrossRef] [PubMed]
48. Da Neto, S.P.L.F.; das Neves, M.B.; Ribeiro-Rodrigues, R.; Page, K.; Miranda, A.E. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz. J. Infect. Dis. 2013, 17, 438-443. [CrossRef] [PubMed]
49. Estrada, V.; Portilla, J. Dyslipidemia related to antiretroviral therapy. AIDS Rev. 2011, 13, 49-56. [PubMed]
50. Rastogi, H.; Jana, S. Evaluation of Inhibitory Effects of Caffeic acid and Quercetin on Human Liver Cytochrome P450 Activities. Phytother. Res. 2014, 28, 1873-1878. [CrossRef] [PubMed]
51. Baer-Dubowska, W.; Szaefer, H.; Krajka-Kuzniak, V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 1998, 28, 735-743. [CrossRef] [PubMed]
52. Huynh, H.T.; Teel, R.W. Effects of plant-derived phenols on rat liver cytochrome P450 2B1 activity. Anticancer Res. 2002, 22, 1699-1703. [PubMed]
53. Nagao, T.; Komine, Y.; Soga, S.; Meguro, S.; Hase, T.; Tanaka, Y.; Tokimitsu, I. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am. J. Clin. Nutr. 2005, 81, 122-129. [PubMed]
54. Kannan, R.R.R.; Arumugam, R.; Thangaradjou, T.; Anantharaman, P. Phytochemical constituents, antioxidant properties and p-coumaric acid analysis in some seagrasses. Food Res. Int. 2013, 54, 1229-1236. [CrossRef]
55. Farag, M.A.; Wessjohann, L.A. Metabolome classification of commercial Hypericum perforatum (St. John's Wort) preparations via UPLC-qTOF-MS and chemometrics. Planta Med. 2012, 78, 488-496. [CrossRef] [PubMed]
56. Berry, L.M.; Zhao, Z.; Lin, M.J. Dynamic Modeling of Cytochrome P450 Inhibition in vitro: Impact of Inhibitor Depletion on IC50 Shifts. Drug Metab. Dispos. 2013, 41, 1433-1441. [CrossRef] [PubMed]
57. Awortwe, C.; Bouic, P.J.; Masimirembwa, C.M.; Rosenkranz, B. Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa - Implications for Herb-Drug Interactions. Drug Metab. Lett. 2013, 7, 83-95. [CrossRef]